In our study, the sensitivity analysis showed that removing SMART-CHOICE trial (14) was consistent with the initial analysis for all outcomes (Supplementary Figure S4), implying that the type of P2Y12 inhibitors may not affect the incidence of ischemic and bleeding events in patients with CAD and CKD. This evidence concerns the gene P2RY12 and chronic kidney disease.